Origano DR Tablet (Delayed Release)

Mycophenolic Acid

Origano DR Tablet (Delayed Release) 360 mg is an active metabolite of the immunosuppressant mycophenolate mofetil, used to treat autoimmune diseases such as lupus and rheumatoid arthritis.

Uses For

Origano DR Tablet (Delayed Release) 360 mg is approved to:

Treat transplant rejection in adults and in children ages 2 years and older.
Prevent the recurrence of kidney allograft rejection in adults.

Brand Name	Origano DR
Type	Tablet (Delayed Release)
Weight	360 mg
Generic	Mycophenolic acid
Manufacturer	Incepta Pharmaceuticals Ltd.
Available in	English বাংলা

Mechanism of Action

Origano DR Tablet (Delayed Release) 360 mg works by blocking an enzyme that is necessary for the body’s defense reaction to foreign substances. By blocking this enzyme, mycophenolic acid reduces the body’s ability to reject an organ transplant.

How Long Does it Take to Work

Origano DR Tablet (Delayed Release) 360 mg can take several weeks to produce therapeutic benefits. However, if combined with other immunosuppressants, the onset of action of mycophenolic acid may be reduced.

Absorption

Origano DR Tablet (Delayed Release) 360 mg is rapidly and completely absorbed after an oral dose. It is also well-absorbed following an intramuscular (IM) injection. The peak plasma concentrations of mycophenolic acid occur about two hours after ingestion.

Route of Elimination

Origano DR Tablet (Delayed Release) 360 mg is readily eliminated by the kidney and has a half-life of about one hour.

Dosage

Dosage in adult kidney transplant patients: The recommended dose of Mycophenolic acid is 720 mg administered twice daily (1440 mg total daily dose).

Dosage in pediatric kidney transplant patients: The recommended dose of Mycophenolic acid in conversion (at least 6 months post-transplant) pediatric patients age 5 years and older is 400 mg/m2 body surface area (BSA) administered twice daily (up to a maximum dose of 720 mg administered twice daily). Pediatric patients with a BSA of 1.19 to 1.58 m2 may be dosed either with three Mycophenolic acid 180 mg tablets, or one 180 mg tablet plus one 360 mg tablet twice daily (1080 mg daily dose). Patients with a BSA of >1.58 m2 may be dosed either with four Mycophenolic acid 180 mg tablets, or two Mycophenolic acid 360 mg tablets twice daily (1440 mg daily dose).

Mycophenolic acid tablets should be taken on an empty stomach, 1 hour before or 2 hours after food intake. Tablets should not be crushed, chewed, or cut prior to ingesting. The tablets should be swallowed whole in order to maintain the integrity of the enteric coating.

Origano DR Tablet (Delayed Release) 360 mg is typically administered in an oral form or by intramuscular injection. The usual dose is two to three times daily, depending on the patient’s condition. The precise dosage and duration of treatment should be determined by a health care professional.

Administration

Origano DR Tablet (Delayed Release) 360 mg is usually taken orally with food, or as an intramuscular injection. It is important to take mycophenolic acid at the same time each day to ensure consistent therapeutic effects.

Side-Effect

Origano DR Tablet (Delayed Release) 360 mg can cause side effects including nausea, vomiting, abdominal pain, diarrhea, headache, dizziness, and fatigue.

Toxicity

Origano DR Tablet (Delayed Release) 360 mg can build up in the bloodstream over time if too much is taken. This can lead to serious side effects and can even be fatal in some cases.

Precaution

It is important to closely follow the dosing instructions from your healthcare practitioner. Patients taking mycophenolic acid should also be aware of any potential drug-drug interactions, as mycophenolic acid may interact with other medications. It is also important to be aware of any potential food and drink interactions.

Interaction

Origano DR Tablet (Delayed Release) 360 mg can interact with many other medications, including nonsteroidal anti-inflammatory drugs (NSAIDs), statins, cyclosporine, tacrolimus, and herbal medicines. Origano DR Tablet (Delayed Release) 360 mg can also interact with some vitamins, minerals, and amino acids. Any medical treatments or surgeries being used should be discussed with your healthcare provider before taking mycophenolic acid.

Disease Interaction

Patients with certain diseases or conditions may be at increased risk for developing side effects or other complications. Therefore, it is important to discuss your medical history with your healthcare provider before taking mycophenolic acid.

Drug Interaction

Origano DR Tablet (Delayed Release) 360 mg can interact with other medications. It is important to tell your healthcare provider about any drugs, over-the-counter products, or herbal supplements you are taking.

Food Interactions

Origano DR Tablet (Delayed Release) 360 mg can interact with certain foods, such as milk, eggs, and soybeans. It is important to follow the dietary instructions provided by your healthcare provider.

Pregnancy Use

Origano DR Tablet (Delayed Release) 360 mg is not recommended for use in pregnant women, as it can cause fetal harm. If you are pregnant and take mycophenolic acid, it is important to tracking your pregnancy with regular ultrasounds.

LactationUse

Origano DR Tablet (Delayed Release) 360 mg is not recommended for use in breastfeeding women. It is important to do thorough research and consult with a healthcare professional prior to taking mycophenolic acid while breastfeeding.

Acute Overdose

If mycophenolic acid is taken in large doses, it can lead to serious health consequences such as vomiting, abdominal pain, fatigue, nausea, rash, and dizziness. If an overdose is suspected, medical attention should be sought immediately.

Contraindication

Origano DR Tablet (Delayed Release) 360 mg is contraindicated in patients with a prior or current hypersensitivity reaction to the drug. It is also not recommended for use in patients with severe renal or hepatic impairment or in patients who are pregnant.

Use Direction

Origano DR Tablet (Delayed Release) 360 mg should be taken exactly as prescribed by a healthcare provider. The dosage and schedule of doses can vary depending on the condition being treated. Swallow the tablet whole and do not crush or chew. If an injection is prescribed, it should be administered intramuscularly. Origano DR Tablet (Delayed Release) 360 mg should always be taken with food.